Safety of potential breast milk exposure to IFN-β or glatiramer acetate
Open Access
- 20 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To determine whether potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA) is safe for the infant. Methods We identified 74 infants born to 69 women with MS who breastfed under IFN-β (n = 39), GA (n = 34), or both (n = 1). Women had been enrolled into the German Multiple Sclerosis and Pregnancy Registry during pregnancy. Data were obtained from standardized, telephone-administered questionnaires completed by the mother during pregnancy and at 1, 3, 6, and 12 months postpartum and the infant's take-home medical record. Results The median duration of exposed breastfeeding was 8.5 months (wide interquartile range: 4.9–12.7 months). Physical growth curves during the first year of life were consistent with national, sex-specific growth curves. Median body measurements were consistent with national medians. Most children (n = 71, 96%) had normal motor and language development. Gross motor delay was reported in 3 children, of whom 1 remained delayed at last follow-up (3.9 years old) and 2 were normal by 0.9 and 4.1 years old. The proportion of children hospitalized at least once (girls n = 2, 7%, and boys n = 6, 14%) and the proportion of children with at least one episode of systemic antibiotic use during the first year of life (girls n = 7, 23%, and boys n = 8, 18%) are consistent with national averages. Conclusion Potential breast milk exposure to IFN-β or GA did not increase the risk of common adverse infant outcomes in the first year of life. Taken together with the benefits of breastfeeding and low biological plausibility of risk, women with MS who wish to resume IFN-β or GA postpartum can be encouraged to breastfeed.Keywords
This publication has 32 references indexed in Scilit:
- Maternal Medication, Drug Use, and BreastfeedingPediatric Clinics of North America, 2013
- Human Milk CompositionPediatric Clinics of North America, 2012
- Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric studyBMC Neurology, 2012
- Transfer of Interferon β-1a into Human BreastmilkBreastfeeding Medicine, 2012
- Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosisNeurology, 2010
- Long-Term Use of Glatiramer Acetate by 11 Pregnant Women with Multiple SclerosisCNS Drugs, 2010
- Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosisJournal of the Neurological Sciences, 2007
- Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled studyThe Lancet Neurology, 2006
- Benefits of breastfeedingNew South Wales Public Health Bulletin, 2005